SPIKEVAX BIVALENTE ORIGINAL/OMICRON BA.4-5 (50 MICROGRAMOS/50 MICROGRAMOS)/ML DISPERSION INYECTABLE

( ARTG ) SPIKEVAX (elasomeran) COVID-19 Vaccine has provisional approval for the indication below:,Active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 in individuals 6 years of age and older.,The use of this vaccine should be in accordance with official recommendations.,The decision has been made on the basis of short-term efficacy and safety data. Continued approval depends on the evidence of longer term efficacy and safety from ongoing clinical trials and post-market assessment.Active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 in individuals 6 years of age and older. The use of this vaccine should be in accordance with official recommendations.